Literature DB >> 26772905

Feasibility of radiolabeled small molecule permeability as a quantitative measure of microbicide candidate toxicity.

Jenell S Coleman1, Edward Fuchs2, Wutyi S Aung2, Mark A Marzinke3, Rahul P Bakshi2, Hans M L Spiegel4, Jennifer Robinson5, Craig W Hendrix2.   

Abstract

OBJECTIVE: To determine the feasibility of using quantitative changes in vaginal permeability to small molecules as a measure of candidate microbicide toxicity. STUDY
DESIGN: Controlled, open-labeled, prospective study. Seven healthy women received a single vaginal dose of hydroxyethylcellulose gel (HEC), nonoxynol-9 (N-9) or K-Y Jelly. Each gel was radiolabeled with a small molecule ((99m)Tc-DTPA) followed by 12-h blood and urine collection. Pharmacokinetic (PK) parameters of (99m)Tc-DTPA were calculated to compare the impact of each gel on vaginal permeability. Each woman served as her own control. The Friedman test with post hoc Wilcoxon test was used to detect differences among the gels.
RESULTS: Vaginal permeability of (99m)Tc-DTPA was highest for the N-9 radiolabel. N-9 plasma area under the concentration curve was 2.7-fold higher (p=.04), and peak concentration was threefold higher (p=.04) compared to HEC. There were no significant PK parameter differences between HEC and K-Y Jelly or between N-9 and K-Y Jelly. Cumulative dose-adjusted median (interquartile range) 12-h timed urine gamma activity was 66.70 × 10(-4)μCi (27.90-152.00) following HEC dosing, 103.00 × 10(-4)μCi (98.20-684.00) following N-9 gel dosing and 20.30 × 10(-4)μCi (11.10-55.90) following K-Y gel dosing. The differences between urine HEC and K-Y Jelly (p=.047) and between N-9 and K-Y Jelly (p=.016) were statistically significant.
CONCLUSIONS: It is feasible to measure differences in vaginal permeability among vaginal gels using a radiolabeled small molecule, though there are permeability differences that require a nuanced understanding of gel composition to interpret the results. IMPLICATIONS: Establishing the safety of both vehicle and active pharmaceutical ingredient is an essential task in microbicide development, to be determined as soon as possible. This study suggests that a combination of microbicide toxicity assessments, that is, cervicovaginal permeability, inspection and histopathology, may need to be studied simultaneously.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  HIV; Microbicide; N-9; Permeability; Spermicide

Mesh:

Substances:

Year:  2016        PMID: 26772905      PMCID: PMC4783221          DOI: 10.1016/j.contraception.2016.01.002

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  19 in total

1.  Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.

Authors:  Quarraisha Abdool Karim; Salim S Abdool Karim; Janet A Frohlich; Anneke C Grobler; Cheryl Baxter; Leila E Mansoor; Ayesha B M Kharsany; Sengeziwe Sibeko; Koleka P Mlisana; Zaheen Omar; Tanuja N Gengiah; Silvia Maarschalk; Natasha Arulappan; Mukelisiwe Mlotshwa; Lynn Morris; Douglas Taylor
Journal:  Science       Date:  2010-07-19       Impact factor: 47.728

2.  Hyperosmolar sexual lubricant causes epithelial damage in the distal colon: potential implication for HIV transmission.

Authors:  Edward J Fuchs; Linda A Lee; Michael S Torbenson; Teresa L Parsons; Rahul P Bakshi; Anita M Guidos; Richard L Wahl; Craig W Hendrix
Journal:  J Infect Dis       Date:  2007-01-23       Impact factor: 5.226

3.  Application of optical coherence tomography for monitoring changes in cervicovaginal epithelial morphology in macaques: potential for assessment of microbicide safety.

Authors:  Kathleen L Vincent; Brent A Bell; Susan L Rosenthal; Lawrence R Stanberry; Nigel Bourne; Yvonne T Cosgrove Sweeney; Dorothy L Patton; Massoud Motamedi
Journal:  Sex Transm Dis       Date:  2008-03       Impact factor: 2.830

Review 4.  Perils at mucosal front lines for HIV and SIV and their hosts.

Authors:  Ashley T Haase
Journal:  Nat Rev Immunol       Date:  2005-10       Impact factor: 53.106

5.  Simultaneous Evaluation of Safety, Acceptability, Pericoital Kinetics, and Ex Vivo Pharmacodynamics Comparing Four Rectal Microbicide Vehicle Candidates.

Authors:  Francisco Leyva; Edward J Fuchs; Rahul Bakshi; Alex Carballo-Dieguez; Ana Ventuneac; Chen Yue; Brian Caffo; Yong Du; Michael Torbenson; Liye Li; Gerald Mullin; Linda Lee; Lisa Rohan; Peter A Anton; Craig W Hendrix
Journal:  AIDS Res Hum Retroviruses       Date:  2015-07-08       Impact factor: 2.205

6.  Evaluation of 99m Tc-DTPA for the measurement of glomerular filtration rate.

Authors:  J F Klopper; W Hauser; H L Atkins; W C Eckelman; P Richards
Journal:  J Nucl Med       Date:  1972-01       Impact factor: 10.057

7.  A Pilot Study Measuring the Distribution and Permeability of a Vaginal HIV Microbicide Gel Vehicle Using Magnetic Resonance Imaging, Single Photon Emission Computed Tomography/Computed Tomography, and a Radiolabeled Small Molecule.

Authors:  Edward J Fuchs; Jill L Schwartz; David R Friend; Jenell S Coleman; Craig W Hendrix
Journal:  AIDS Res Hum Retroviruses       Date:  2015-08-05       Impact factor: 2.205

8.  Identification of personal lubricants that can cause rectal epithelial cell damage and enhance HIV type 1 replication in vitro.

Authors:  Othell Begay; Ninochka Jean-Pierre; Ciby J Abraham; Anne Chudolij; Samantha Seidor; Aixa Rodriguez; Brian E Ford; Marcus Henderson; David Katz; Thomas Zydowsky; Melissa Robbiani; José A Fernández-Romero
Journal:  AIDS Res Hum Retroviruses       Date:  2011-03-08       Impact factor: 2.205

9.  Optical coherence tomography for assessment of microbicide safety in a small animal model.

Authors:  Brent A Bell; Kathleen L Vincent; Nigel Bourne; Gracie Vargas; Massoud Motamedi
Journal:  J Biomed Opt       Date:  2013-04       Impact factor: 3.170

10.  Absorption and excretion of radioactivity after intravaginal administration of an advanced delivery system of 14C-flutrimazole vaginal cream to postmenopausal women.

Authors:  B John; S G Wood; J Ramis; I Izquierdo; J Forn
Journal:  Arzneimittelforschung       Date:  1998-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.